Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211240 | 1.00 | MTNR1A (0.53) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL8324607 | 0.83 | MTNR1A (0.71) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL30518933 | 0.77 | MTNR1A (0.64) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL5205624 | 0.77 | NPC1 (0.69) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL3197669 | 0.76 | MTNR1A (0.63) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL3197659 | 0.76 | MTNR1A (0.63) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL3188745 | 0.76 | ENPP3 (0.69) | MTNR1AMTNR1BHTTNPC1RAB9A | |
| SCHEMBL3210874 | 0.76 | MTNR1A (0.59) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL3210865 | 0.76 | MTNR1A (0.59) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL3995294 | 0.73 | ENPP3 (0.59) | HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | MTNR1A 209/4885MTNR1B 154/4885HTT 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.